Myriad RBM said this week that it has signed a collaboration agreement with pharma firm Sanofi and Canada's Population Health Research Institute to explore protein biomarkers linked to diabetes.

Under the agreement, Myriad RBM will run more than 8,000 serum samples from the Outcome Reduction with Initial Glargine Intervention, or ORIGIN, diabetes study on its DiscoveryMAP 250+ immunoassay panel.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.